Photo taken from Heidi Ko/LinkedIn
Sep 8, 2024, 14:49
Heidi Ko: How molecular classification impacts targeted therapy options
Heidi Ko, Medical Director, Medical Affairs at shared a post on LinkedIn:
“Uterine cancer is the most common gynecologic cancer in the U.S., with increasing incidence and mortality rate. This Molecular Tumor Board case presented is about a 56-year-old female patient with uterine cancer and an underlying POLE V411L alteration. Join us as we discuss molecular subgroups in uterine cancer and how molecular classification impacts targeted therapy options.”
Read further.
Source: Heidi Ko/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43